publication venue for
- Natural Protest 2020
- Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis. 28:1-166. 2024
- Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. 26:1-60. 2022
- Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. 26:1-148. 2022
- Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. 25:1-62. 2021
- Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. 23:1-190. 2019
- Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. 23:1-88. 2019
- A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study).. 15:1-132. 2011
- Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). 15:23-32. 2011
- Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. 11:1-+. 2007
- Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. 11:iii-164. 2007
- The management of dyspepsia: a systematic review.. 4:iii-189. 2000
- Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.. 3:i-98. 1999
- Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). 15:23-32.
- Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal. 13:63-68.